Sight Sciences reaffirms FY23 revenue guidance; WPS proposes limiting MIGS coverage for OMNI

Sight Sciences, Inc.

Reaffirmed FY2023 revenue guidance of $89M-$94M (25%-32% growth YoY); quarterly adjusted opex ~$30.5M.
WPS (Medicare contractor) proposed LCD classifying non-implantable MIGS as investigational; would make OMNI non-covered in 6 states.
WPS-served states (KS, NE, MO, IA, IN, MI) accounted for ~8% of Surgical Glaucoma revenue in 2022.
Company strongly disagrees, plans to present clinical evidence at WPS meeting June 14 and comment period through July 15.
Precedent: Palmetto GBA withdrew similar 2020 LCD after ophthalmic community pushback.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.